-
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011;30:215-8. -
Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
Prenat Diagn 2011;31:802-8. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Maternal serum progesterone-induced blocking factor at 11-13 weeks gestation in spontaneous early preterm delivery.
Beta J, Szekeres-Bartho J, Skyfta E, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;29:197-200. -
Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH.
Prenat Diagn 2011;31:33-7. -
Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
Obstet Gynecol 2011;117:293-8. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
Prenat Diagn 2011;31:38-45. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
Fetal Diagn Ther 2011;29:301-6. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Lymphatic capillary hypoplasia in the skin of fetuses with increased nuchal translucency and Turner's syndrome: comparison with trisomies and controls.
Von Kaisenberg CS, Wilting J, Dörk T, Nicolaides KH, Meinhold-Heerlein I, Hillemanns P, Brand-Saberi B.
Mol Hum Reprod 2010;16:778-89. -
Synergy of Total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of Trisomy 21.
Tsui NB, Akolekar R, Chiu RW, Chow KC, Leung TY, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2010;56:73-81. -
Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome.
Tsui DW, Lam YM, Lee WS, Leung TY, Lau TK, Lau ET, Tang MH, Akolekar R, Nicolaides KH, Chiu RW, Lo YM, Chim SS.
PLoS One 2010;5:e15069. -
Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker.
Tong YK, Chiu RW, Akolekar R, Leung TY, Lau TK, Nicolaides KH, Lo YM.
PLoS One 2010;5:e15244. -
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:547-50. -
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
Spencer K, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:235-40. -
Additional first-trimester ultrasound markers.
Sonek J, Nicolaides K.
Clin Lab Med 2010;30:573-92.